Estrogen Replacement Therapy and Breast Cancer Survival in a Large Screening Study
Open Access
- 3 February 1999
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 91 (3) , 264-270
- https://doi.org/10.1093/jnci/91.3.264
Abstract
BACKGROUND: Hormone replacement therapy has been associated in some studies with reductions in breast cancer mortality among women who develop this disease. It is unclear whether this association reflects the biologic activity of the hormones or the earlier detection of tumors among hormone users. We examined breast cancer mortality among women who were diagnosed with axillary lymph node-negative and node-positive breast cancer according to the currency of estrogen use at diagnosis. METHODS: Vital status through June 1995 was determined for 2614 patients with postmenopausal breast cancer diagnosed during the period from 1973 to January 1981. We estimated adjusted hazard-rate ratios (adjusting for tumor size, age, race, Quetelet [body mass] index, and number of positive lymph nodes in women with node-positive disease) and unadjusted cumulative probabilities of breast cancer death over time since diagnosis. RESULTS: Among patients with node-negative disease, rate ratios for breast cancer mortality associated with current use compared with nonuse at diagnosis were 0.5 (95% confidence interval [CI] = 0.3-0.8) until 144 months after diagnosis and 2.2 (95% CI = 0.9-5.2) thereafter. Mortality was not statistically significantly lower in past users. The cumulative probabilities of breast cancer mortality at the end of follow-up were 0.14, 0.14, and 0.09 in nonusers, past users, and current users, respectively. Among women with node-positive disease, the rate ratios associated with current and past use were both 0.5 until 48 months after diagnosis (95% CI = 0.3-0.8 for current users; 95% CI = 0.3-0.9 for past users) and were 1.1 (95% CI = 0.7-1.7) and 1.8 (95% CI = 1.2-2.7), respectively, thereafter. The cumulative probabilities of breast cancer mortality were 0.32, 0.39, and 0.27 in nonusers, past users, and current users, respectively. CONCLUSIONS: Patients with breast cancer who were using replacement estrogens at the time of diagnosis experienced reductions in breast cancer mortality, which waned with the time since diagnosis.Keywords
This publication has 29 references indexed in Scilit:
- Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancerThe Lancet, 1997
- Postmenopausal Hormone Therapy and MortalityNew England Journal of Medicine, 1997
- Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy—long-term follow-up of a Swedish cohortInternational Journal of Cancer, 1996
- Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United StatesCancer Causes & Control, 1996
- EVIDENCE OF A HEALTHY ESTROGEN USER SURVIVOR EFFECTEpidemiology, 1995
- Hormone replacement therapy and breast cancer mortality in Swedish women: results after adjustment for ?healthy drug-user? effectCancer Causes & Control, 1993
- Type of postmenopausal hormone use and risk of breast cancer: 12-year follow-up from the Nurses' Health StudyCancer Causes & Control, 1992
- Mortality in a cohort of long‐term users of hormone replacement therapy: an updated analysisBJOG: An International Journal of Obstetrics and Gynaecology, 1990
- PROGNOSIS AFTER BREAST CANCER DIAGNOSIS IN WOMEN EXPOSED TO ESTROGEN AND ESTROGEN-PROGESTOGEN REPLACEMENT THERAPYAmerican Journal of Epidemiology, 1989
- Long‐term surveillance of mortality and cancer incidence in women receiving hormone replacemen therapyBJOG: An International Journal of Obstetrics and Gynaecology, 1987